What Катэна Treats: Main Uses and Benefits

Катэна (Gabapentin) is commonly used to provide symptomatic relief across specific neurological conditions where symptoms arise from abnormal nerve activity or heightened neuronal excitability. The medicine has established therapeutic domains centered on pain and seizure management.

---

The medicine is relevant for easing symptoms related to heightened physiological activity, including: partial onset seizures in epilepsy, chronic neuropathic pain such as postherpetic neuralgia (pain after shingles), and the symptoms of moderate-to-severe Restless Legs Syndrome (RLS). It is considered relevant in clinical settings that involve acute or unstable symptom patterns. The medication plays a role in managing symptoms by helping to stabilize nerve cell activity.

Quick Fact: Relief for Neuropathic Discomfort

This medicine is relevant for easing symptom clusters that may become intense or disruptive, such as burning, shooting, or stabbing sensations that originate from nerve dysfunction. It is commonly used across domains where additional symptomatic support is needed. Катэна provides support that helps ease the overall symptom burden, contributing to improved day-to-day comfort. It may assist with maintaining functional stability and supports general well-being during symptomatic phases.

Regulatory References

1. NIH MedlinePlus Drug Information

Official Eligibility Rules for Катэна (Gabapentin)

The ability to use this medicine is strictly determined by regulatory documentation concerning patient population, age, and existing health status. The primary determinant of non-eligibility is a history of adverse reaction or hypersensitivity.

Category	Regulatory Status
Contraindicated Populations	Individuals with a known hypersensitivity to Gabapentin or its excipients. Patients who have developed a severe, life-threatening reaction such as DRESS syndrome or Stevens-Johnson syndrome (SJS) from prior use must not take this medicine.
Age-Based Eligibility	Use for neuropathic pain is established in adults (ge 18 years). Use for partial seizures is established in adults and pediatric patients ge 3 years of age (US label) or ge 6 years (EU label). Efficacy is not established for neuropathic pain in pediatric patients le 17 years of age.
Renal Function Status	Patients with renal impairment (decreased kidney function) must have their eligibility restricted and their dose mandatorily adjusted based on their creatinine clearance values. This is also required for Older Adults (Geriatric population), who are more likely to have reduced renal function.
Life Stage Restrictions	Use in pregnant women is generally not recommended unless the benefit clearly outweighs the potential risks. Nursing mothers are generally not recommended to use the medicine, as Gabapentin is known to be excreted into human milk.

Катэна Interactions with other medicines and products

Interaction Scope

Documented interactions primarily involve two major domains: pharmacodynamic reinforcement with central nervous system (CNS) depressants and pharmacokinetic modification involving oral absorption. Co-administration of opioids (such as morphine or hydrocodone), alcohol, or other CNS depressants can cause additive effects, which manifest as increased somnolence, sedation, and a significant risk of respiratory depression. In the case of opioids, this pharmacodynamic risk is compounded by a documented increase in Gabapentin exposure (AUC).

Interaction Classifications (Regulatory Basis)

The interaction with CNS depressants, particularly in combination with opioids, is classified as a high-risk combination and is subject to an FDA Safety Warning due to the potential for serious and sometimes fatal respiratory depression. Conversely, antacids containing aluminum or magnesium reduce Gabapentin's bioavailability by approximately 20%. No clinically significant pharmacokinetic interactions have been established with the traditional anti-epileptic drugs, including phenytoin, carbamazepine, or valproic acid, reflecting Gabapentin’s lack of appreciable liver metabolism.

Resulting Interaction Structure

The official interaction profile mandates a timing-based rule to mitigate absorption interference: Gabapentin must be taken at least two hours following administration of aluminum- or magnesium-containing antacids. Furthermore, the risk of serious respiratory depression is formally noted to be elevated in the elderly population and patients with existing respiratory risk factors.

Targeting the Presynaptic alpha2delta-1 Subunit

Катэна (Gabapentin) exerts its primary mechanism by binding with high affinity to the auxiliary alpha2delta-1 subunit of Voltage-Gated Calcium Channels located on the presynaptic terminals of nerve cells. This interaction inhibits the subunit's trafficking, reducing the functional density of these calcium channels on the cell surface.

⬇️ Modulation of Excitatory Neurotransmitter Release

This reduction in functional calcium channels limits the flow of calcium ions into the nerve ending, which is the necessary signal for the exocytosis of neurotransmitters. The mechanism restricts the presynaptic calcium flow, resulting in a measurable reduction in the release rate of excitatory neurotransmitters such as Glutamate in hyperactive neural pathways.

Modulation of Neuronal Hyperexcitability

The sequence of reduced excitatory signaling contributes to the modulation of neuronal hyperexcitability within the involved circuits. This action modulates the neuronal firing rate, contributing to the dampening of signal amplification characteristic of sensitized signal pathways.

How to use Катэна

Катэна (Gabapentin) is administered exclusively via the oral route and is available in capsules, tablets, and an oral solution. The administration protocol is defined by clinical standards, emphasizing a careful process to manage appropriate drug levels.

---

Administration Guidelines

Administration Entity	Official Labeled Instruction
Route and Forms	Oral administration only. The medicine is available as capsules, tablets, and an oral solution.
Dosing Schedule	Initial dosing requires a gradual upward titration over several days. The typical adult maintenance range is 900 mg to 3600 mg per day in divided doses.
Frequency and Timing	The standard schedule is three times a day (TID). The interval between doses should not exceed 12 hours to maintain consistent control. The medication can be taken with or without food.
Special Intake Conditions	Antacids containing aluminum or magnesium must be administered at least two hours after Gabapentin to avoid reduced absorption. Capsules must be swallowed whole.

---

Population-Specific Adjustments

A mandatory dose adjustment is required for all patients with impaired renal function, and the daily dose must be reduced based on creatinine clearance. For patients undergoing hemodialysis, a supplemental dose is required following each dialysis session. Pediatric dosing is determined based on the patient's body weight.

Discontinuation Protocol

If treatment needs to be stopped, it must be done gradually over a minimum period of seven days to follow established procedural requirements.

Research evidence / Overview of studies for Катэна (Gabapentin)

Evidence for Management of Chronic Nerve Pain (Neuropathic Pain)

Research exploring the active compound in Катэна for chronic neuropathic pain was primarily conducted in research exploring how symptoms change over time in conditions such as postherpetic neuralgia and painful diabetic neuropathy. Clinical evaluation relies mainly on randomized, placebo-controlled trials (RCTs) and systematic reviews, which applied in studies examining patient-reported experiences related to physical discomfort. These trials were typically short-term, applied in research contexts involving fluctuating or unstable symptoms, with studies observing responses over defined time intervals.

Research in Postherpetic Neuralgia (PHN)

The compound was studied for postherpetic neuralgia (PHN), which is a condition associated with acute or disruptive episodes of discomfort following shingles. Research explored the compound in adult populations, including older adults, whose condition involved periods of heightened symptoms. Studies monitored patient-reported outcomes describing perceived discomfort, particularly the severity of daily pain and interference with sleep. Findings describe patterns observed in the studies over observation periods, which often lasted around 7 to 8 weeks. However, there is limited information for long-term outcomes, as follow-up durations were typically short-term and results apply only to the populations studied in these initial trials.

Research in Painful Diabetic Neuropathy (PDN)

Research explored the use of the compound for painful diabetic neuropathy (PDN), a condition where symptoms may vary in intensity due to nerve damage caused by diabetes. Studies focused on adult populations, and research highlights changes measured during the study period, primarily related to pain severity scores and overall sleep quality. The available evidence contributes to the scientific understanding of PDN, and data show patterns related to response variability, and certainty remains low regarding universal findings across the observed populations. Furthermore, the evidence is limited to short-to-intermediate term follow-up, and subgroup findings are uncertain for certain groups of patients with diabetes-related comorbidities.

Evidence for Use as Adjunctive Therapy in Epilepsy

The compound was evaluated in studies focusing on its use alongside other anti-epileptic drugs for managing partial onset seizures. These studies included both adult patients and pediatric patients as young as 3 years old. Research examined outcomes related to episodic or acute changes by monitoring the reduction in the frequency of partial seizures. Studies report how symptoms evolved in the observed populations during the trial period. The evidence contributes to understanding symptom patterns related to these specific seizures, but research describes that the compound was not studied for generalized epilepsy types, such as absence seizures.

Evidence for Management of Restless Legs Syndrome (RLS)

Research examined the use of the compound in trials for adults with moderate-to-severe Restless Legs Syndrome (RLS), a condition characterized by fluctuating or episodic manifestations. Research explored short-term symptom changes, with studies focusing on episodes where symptoms become more noticeable, particularly tracking changes in the International RLS Rating Scale scores and patient-reported outcomes describing perceived discomfort related to sleep quality. Findings indicate patterns observed in the studies related to symptom severity, but data are still emerging. Much of the evidence for this specific condition was derived from studies of a different formulation of the active ingredient, and data show patterns related to absorption variability, and evidence remains limited for the original formulation in this specific context.

Long-Term Evidence and Durability of Response

Clinical trials predominantly assessed short-term and intermediate-term changes in symptoms. As a result, long-term effects are not fully established for any of the studied indications, particularly regarding the durability of any observed response over periods extending beyond a few months. This is a common research limitation frame where data for sustained outcomes and long-term use in daily-life functioning remain insufficient. Research is ongoing, but evidence highlights what is known—and what is still uncertain—about outcomes over many years.

Research in Specific and Special Populations

Evidence has included studies in older adults (75 years) with postherpetic neuralgia and pediatric patients (3 years and older) with partial onset seizures. These studies help show what has been observed so far in these specific groups. However, research exploring certain other groups, such as those with significant comorbidities or pregnant populations, is limited. The evidence quality varies across studies when examining specific subgroups, meaning that results apply only to the populations studied under those specific research conditions.

Understanding Research Gaps and Uncertainties

The evidence landscape provides context but not individual predictions. A key limitation is that follow-up durations were limited in many pivotal trials, and long-term effects are not fully established. Additionally, findings were mixed regarding the proportion of patients who reported changes on specific pain intensity scales in chronic pain studies. This means research provides insight into short-term changes but cannot determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted. Data for certain subgroups remain insufficient, and comparative evidence against all other treatment options is often lacking.

Common questions about Катэна (FAQ)

Q: Is it normal to experience swelling in the hands or feet while on Катэна?

Official regulatory documents describe swelling in the hands or feet, known as peripheral oedema, as a common adverse reaction associated with this medicine. Patients who experience severe or bothersome swelling should discuss this symptom with a healthcare professional.

Q: Can taking Катэна cause feelings of dizziness or drowsiness?

Yes, according to official product information, feelings of dizziness and drowsiness (somnolence) are noted as very common adverse reactions. The potential for these effects is documented, and they may influence a person’s ability to perform certain daily activities safely.

Q: Are there withdrawal symptoms when stopping Катэна, even if taken as prescribed?

Official documents indicate that abruptly stopping the medicine carries a specific regulatory warning about the risk of increased seizure frequency. Additionally, non-seizure-related discontinuation effects, such as increased anxiety, difficulty sleeping, and nausea, have been noted in case reports when the medicine is stopped suddenly. For these reasons, a controlled, gradual reduction protocol is defined in regulatory guidelines.

Q: How is the process of stopping Катэна generally described in medical guidelines?

The official regulatory documents describe a mandatory discontinuation protocol. This process requires the medicine to be reduced gradually over a minimum period of seven days. This measured approach is used in an effort to reduce the potential risk of symptoms like increased seizure activity.

Q: Can people with diabetes take Катэна, and are there special considerations?

Катэна is an established treatment studied for conditions such as Painful Diabetic Neuropathy. Official safety documents note that metabolic adverse reactions, including changes in blood sugar levels (blood glucose fluctuations), may occur as a side effect. Patients managing diabetes should understand this possibility is described in official documentation.

Q: Does Катэна affect concentration or mental clarity?

Official safety warnings indicate that this medicine can cause nervous system effects like dizziness, drowsiness, and unsteadiness. These effects may impair a person's coordination and ability to think clearly. Because of these potential effects, it is generally advised that a person observe how the medicine affects them before engaging in activities that require full focus.

Q: Is Катэна considered a long-term treatment or is it usually for short-term use?

The medicine is approved for managing chronic (long-lasting) conditions, such as neuropathic pain. While many pivotal trials assess short-term changes, the drug is studied in clinical trials with follow-up periods extending up to a year, supporting its intended use as a longer-term treatment option.

Q: How long does the effect of one dose of Катэна last in the body?

The time it takes for half of the medicine to be cleared from the body (known as the elimination half-life) is typically 5 to 7 hours in adults with healthy kidney function. This information is part of the pharmacokinetic profile that informs the required dosing frequency.

Q: Does taking Катэна affect a person’s driving ability or ability to operate heavy machinery?

Official regulatory warnings are provided because the medicine can cause side effects such as drowsiness, dizziness, and impaired coordination. Official warnings state that patients should not drive or operate complex machinery until they have assessed the potential impact of the medicine on their abilities.

Q: What is the difference between immediate-release and extended-release forms of the drug?

The active ingredient is available in both standard (immediate-release) and specialized (extended-release) formulations. Official regulatory documents specify that these different forms are not interchangeable and require careful management. This is because each formulation is processed by the body in a distinct way (pharmacokinetic profile).

Q: Does Катэна have an impact on sexual function?

Post-marketing surveillance reports have associated the use of this medicine with adverse reactions affecting the reproductive system. Specifically, this may include difficulty achieving orgasm, or anorgasmia.

Q: Where does the body excrete or get rid of Катэна?

The medicine is eliminated from the body primarily through the kidneys. This process, known as renal clearance, is a key factor in determining how the medicine is managed. For this reason, official dosing rules require adjustment for patients who have reduced kidney function.

Q: Does Катэна interact with herbal supplements?

Official guidance emphasizes that patients inform their healthcare provider about all herbal remedies and supplements being used. There is a general caution regarding co-administration with any supplement that may cause dizziness or drowsiness, as this could potentially worsen existing side effects of the medicine.

Q: Is it possible for Катэна to cause or increase the frequency of tremors?

Tremor (involuntary shaking) is listed as a common adverse event affecting the nervous system in the official safety profile. Tremor is a common side effect, and any new or worsening symptoms are typically managed through consultation with a healthcare professional.

How to Store and Dispose of Катэна (Gabapentin)

Gabapentin capsules and tablets must be stored at 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C (86 F), and must be protected from moisture. The product should be kept in its original container.

The oral solution requires cold storage (2 C to 8 C) prior to being dispensed. Once dispensed, the solution should be stored at controlled room temperature and is stable for 9 months.

All forms of the medicine must be stored out of the sight and reach of children.

Expired or unused product should not be disposed of via household waste or wastewater. Disposal should be carried out through an approved medicine take-back program or returned to a pharmacy.